Cellebrite DI (NASDAQ:CLBT) Issues Quarterly Earnings Results

Cellebrite DI (NASDAQ:CLBT) announced its earnings results on Thursday. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02, Briefing.com reports. Cellebrite DI had a negative net margin of 24.94% and a positive return on equity of 173.14%. The company had revenue of $89.60 million for the quarter, compared to the consensus estimate of $85.34 million. During the same period in the previous year, the business earned $0.03 EPS. The company’s revenue was up 25.8% on a year-over-year basis.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $11.88 on Friday. The firm has a 50-day simple moving average of $11.12 and a 200 day simple moving average of $9.86. Cellebrite DI has a twelve month low of $5.37 and a twelve month high of $12.50. The stock has a market cap of $2.45 billion, a PE ratio of -27.63, a PEG ratio of 2.04 and a beta of 1.51.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. William Blair raised shares of Cellebrite DI from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 13th. Lake Street Capital assumed coverage on shares of Cellebrite DI in a research note on Friday, April 19th. They issued a “buy” rating and a $13.00 price target on the stock. Needham & Company LLC upped their price target on shares of Cellebrite DI from $13.50 to $14.00 and gave the stock a “buy” rating in a research note on Friday. Bank of America upped their price target on shares of Cellebrite DI from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Finally, Craig Hallum upped their price target on shares of Cellebrite DI from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $12.50.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.